Selective inhibition of CDK7 ameliorates experimental arthritis in mice

Area of Science:

• Immunology
• Pharmacology
• Molecular Biology

Background:

• Cyclin-dependent kinases (CDKs) are increasingly recognized as potential anti-inflammatory therapeutic targets.
• Cyclin-dependent kinase 7 (CDK7) plays a role in regulating gene transcription and cell cycle progression.
• Targeting CDK7 offers a novel strategy for managing inflammatory conditions like arthritis.

Purpose of the Study:

• To investigate the therapeutic efficacy of BS-181, a selective CDK7 inhibitor, in a mouse model of collagen-induced arthritis (CIA).
• To elucidate the underlying molecular mechanisms by which BS-181 exerts its anti-arthritic effects.

Main Methods:

• Mice with established CIA were treated with BS-181 (10 mg/kg) intraperitoneally twice daily for two weeks.
• Arthritis severity, joint histopathology, serum cytokine levels, anti-type II collagen antibodies (anti-CII), IkB kinase (IKK)-β/NF-κB activation, and Th17 cell ratios were assessed.
• In vitro studies involved stimulating splenocytes from CIA mice with collagen type II (CII) in the presence or absence of BS-181.

Main Results:

• BS-181 treatment significantly reduced clinical arthritis scores and histological joint damage in CIA mice.
• Serum levels of pro-inflammatory cytokines (IL-6, IL-1β, IL-17) and anti-CII IgG2a antibodies were decreased.
• BS-181 inhibited IKK-β/NF-κB signaling pathway activation and reduced the Th17 cell ratio in arthritic joints.
• In vitro, BS-181-treated splenocytes produced lower levels of pro-inflammatory cytokines.

Conclusions:

• CDK7 inhibition with BS-181 demonstrates significant therapeutic potential for treating collagen-induced arthritis.
• The anti-arthritic effects of BS-181 are likely mediated through the suppression of IKK-β/NF-κB activation and the Th17 cell response.
• BS-181 represents a promising novel therapeutic agent for inflammatory arthritis.